Effect of switch from EquMet combination tablet to METOANA combination tablet

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000040960
• Lead Sponsor: Kurihara Clinic of Internal Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-03-25
• Study Start: 2020-06-30
• Results First Posted: 2021-01-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 142

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who are treated by combination of metformin / vildagliptin fixed-dose combination tablet LD and HD 2. Patients who changed the dose of metformin / vildagliptin fixed-dose combination tablet during the metformin / vildagliptin fixed-dose combination tablet administration period 3. Patients who changed the dose of metformin / anagliptin fixed-dose combination tablet during the metformin / anagliptin fixed-dose combination tablet administration period 4. Patients who changed the type or dose of hypoglycemic agents or antihyperlipidemic agents 5. Patients who are treated by dialysis or patients with severe renal impairment (eGFR < 30 mL/min/1.73m2) at baseline 6. Female patients who are pregnant, breastfeeding, possibly pregnant, or planning to become pregnant 7. Patients who denied the use of clinical medical records to the study 8. Patients with any conditions that physicians thought to be inappropriate to participate in the study such as poor adherence

Study & Design

• Study Type: Observational
• Study Design: Not specified